The hospital points to returning hunger, cravings and plateaus as cues, says any dose change should go through a doctor, and pushes readers to book a consult.
Recap by typeshit. Post by @altiushospitals on Instagram.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
WCNC Charlotte talks with a bariatric surgeon about why the drug nicknamed RETA is drawing attention even though it has no FDA approval.
The Economic Times reports Bayer AG is weighing opportunities in products aimed at side effects people get on GLP-1 drugs.
Loading…